Chimeric antigen receptor therapies have transformed the treatment of certain blood cancers, producing dramatic remissions in patients with leukemia and lymphoma who had exhausted every other option. Yet when researchers have tried to extend the same strategy to solid tumors—breast, lung, pancreatic, and skin cancers among them—they have run into a stubborn obstacle: most of the molecular targets that CAR-engineered cells can recognize sit on the surface of tumor cells, and very few of them are exclusive to cancer. Healthy tissues often carry the same proteins, creating a dangerous risk of off-tumor toxicity. A team at the Center for Cell-Based Therapy at the University of São Paulo in Ribeirão Preto, Brazil, has now reported a way around this bottleneck, engineering natural killer cells to recognize a hidden target buried inside tumor cells and demonstrating that the approach can shrink melanoma in living animals.
The trick lies in a class of receptors known as TCR-like CARs. Unlike conventional CARs, which bind surface proteins directly, TCR-like receptors are designed to mimic the specificity of T-cell receptors: they recognize short peptide fragments derived from intracellular proteins that are chopped up, shuttled to the cell surface, and displayed on human leukocyte antigen molecules. This presentation system turns the interior of the cell into a display window. If a tumor cell produces an abnormal or abnormally abundant protein, fragments of that protein end up on the surface as peptide-HLA complexes, even though the intact protein itself never leaves the cell. Antibody-based CARs cannot see these complexes; TCR-like CARs can.
The Brazilian team, led by corresponding author Virginia Picanço-Castro together with first author Sima Ebrahimabadi and colleagues, chose to target the cancer-testis antigen MAGE-A4, an intracellular protein that is normally silent in adult tissues except for the testis, which is immunologically privileged, but is re-expressed at high levels in a range of malignancies, including melanoma, sarcoma, and multiple myeloma. Their CAR was built to recognize a specific MAGE-A4-derived peptide presented by the HLA-A*02:01 molecule, one of the most common HLA types in human populations. The construct incorporated CD3ζ, the canonical activation domain used in CAR design, paired with an intracellular signaling domain derived from GITR, a co-stimulatory receptor known to bolster T-cell and NK-cell function.
What makes the study distinctive is its choice of effector cell. Most CAR therapy research has focused on T cells, but natural killer cells offer several practical advantages. NK cells can be harvested from healthy donors and used in an allogeneic setting without triggering graft-versus-host disease, they carry their own arsenal of activating and inhibitory receptors that can be harnessed for additional tumor recognition, and they do not persist indefinitely in the patient, which may limit long-term toxicity. The researchers evaluated their MAGE-A4 CAR in two platforms: the NK-92 cell line, a well-established laboratory model for NK-cell engineering, and primary peripheral blood NK cells isolated from healthy donors, which better approximate the product that would eventually reach patients.
One of the most striking findings came from metabolic profiling of the engineered NK-92 cells. CAR expression did not simply arm the cells with a new recognition capability; it fundamentally improved their energetic condition. The CAR-positive cells showed increased glycolysis, elevated basal respiration, and greater ATP production compared with unmodified controls. Metabolic fitness is increasingly recognized as a critical determinant of whether immune cells can sustain their attack inside the hostile, nutrient-poor environment of a solid tumor, where oxygen is scarce and glucose is contested. By demonstrating that TCR-like CAR expression enhances the metabolic engine of NK cells, the study adds a dimension to CAR design that goes beyond simple target recognition.
Functionally, the engineered cells proved far more lethal to tumor targets than their unmodified counterparts. When exposed to MAGE-A4-positive cell lines—the melanoma line A375, the osteosarcoma line U2OS, and the multiple myeloma line U266—the CAR-NK cells killed significantly more tumor cells. Crucially, they left the MAGE-A4-negative colorectal cancer line HCT116 largely untouched, confirming that the killing was antigen-specific rather than a nonspecific boost in aggression. The enhanced cytotoxicity was accompanied by measurable changes in the machinery of cell killing: the CAR-NK cells showed increased CD107a degranulation, a marker of lytic granule release, along with elevated expression of granzyme B and perforin, the two pore-forming and enzyme-mediated weapons NK cells use to dismantle target cells from within.
The inflammatory output of the engineered cells also rose. CAR-NK cells produced higher levels of the cytokines TNF-α and IFN-γ upon encountering MAGE-A4-positive targets. These signaling molecules do more than reflect activation; they recruit and shape the broader immune response within the tumor microenvironment, potentially converting a localized cell-killing event into a wider immunological alarm. The same pattern of enhanced killing and cytokine secretion was reproduced in primary NK cells carrying the CAR, an important validation step, since laboratory cell lines sometimes behave very differently from the primary cells that would be used clinically.
The decisive test came in vivo. The researchers implanted A375 human melanoma cells into immunodeficient mice and treated them with the MAGE-A4 CAR NK-92 cells. The engineered cells demonstrated potent antitumor activity, controlling the xenografted tumors in a way that unmodified NK-92 cells could not. Xenograft models have well-known limitations—they lack a complete human immune system, and tumor biology in mice does not perfectly mirror human disease—but they remain an essential preclinical gate. Passing that gate means the therapy has shown it can function not just in a culture dish, where nutrients and oxygen are abundant and targets are easily reached, but inside a living organism where cells must traffic, survive, and kill under physiological pressure.
The work, published in Cancer Immunology, Immunotherapy, arrives amid growing enthusiasm for MAGE-A4 as a target in cellular immunotherapy. T-cell receptor therapies directed at MAGE-A4 have already entered clinical trials for sarcoma and other solid tumors, and the antigen’s restricted expression pattern makes it one of the safer intracellular targets currently under investigation. Extending that targeting logic to NK cells, and combining it with co-stimulatory signaling through GITR, offers a potentially off-the-shelf alternative that could be manufactured from donor blood and administered without the individualized production timelines that autologous T-cell therapies require. The authors note that their findings collectively demonstrate that TCR-like targeting of MAGE-A4 using CAR-engineered NK cells enhances metabolic fitness, effector function, and antitumor activity, positioning the approach as a promising immunotherapeutic strategy for MAGE-A4-positive solid tumors.
Considerable work remains before such a therapy could reach patients. The study was conducted in cell lines and xenograft models, and questions about persistence, trafficking to dense solid tumor masses, and behavior in the presence of a full human immune system will need answers in more sophisticated models and, eventually, clinical trials. HLA restriction also means the therapy would apply only to patients carrying HLA-A*02:01, narrowing the eligible population, though that allele is common enough to make the approach broadly relevant. Tumor heterogeneity poses another challenge: cancers that downregulate MAGE-A4 or lose HLA expression could escape recognition, a known vulnerability of all peptide-HLA-directed strategies. Even so, the convergence of metabolic enhancement, antigen specificity, and in vivo efficacy reported here gives researchers a concrete template for engineering NK cells against the hidden interior world of the cancer cell, a world that conventional antibody-based therapies have never been able to reach.
Subject of Research: TCR-like CAR-engineered NK cells targeting the MAGE-A4/HLA-A*02:01 peptide-HLA complex for solid tumor immunotherapy.
Article Title: TCR-like MAGE-A4/HLA-A*02:01 CAR-NK cells enhance antitumor effector function and control melanoma xenografts
Article References: TCR-like MAGE-A4/HLA-A*02:01 CAR-NK cells enhance antitumor effector function and control melanoma xenografts. (n.d.). https://doi.org/10.1007/s00262-026-04551-4
Image Credits: AI Generated
DOI: 10.1007/s00262-026-04551-4
Keywords: chimeric antigen receptor, natural killer cells, TCR-like CAR, MAGE-A4, HLA-A*02:01, solid tumor, melanoma, immunotherapy, metabolic fitness, xenograft model, granzyme B, GITR signaling
Cite Scienmag News
APA
MLA
Chicago
Nathaniel Bowman. (September 23, 2026). Engineered NK Cells Target Hidden Cancer Antigen to Control Melanoma in Mice. Scienmag. https://scienmag.com/engineered-nk-cells-target-hidden-cancer-antigen-to-control-melanoma-in-mice/
Nathaniel Bowman. “Engineered NK Cells Target Hidden Cancer Antigen to Control Melanoma in Mice.” Scienmag, 23 September 2026, https://scienmag.com/engineered-nk-cells-target-hidden-cancer-antigen-to-control-melanoma-in-mice/. Accessed 23 September 2026.
Nathaniel Bowman. “Engineered NK Cells Target Hidden Cancer Antigen to Control Melanoma in Mice.” Scienmag. September 23, 2026. https://scienmag.com/engineered-nk-cells-target-hidden-cancer-antigen-to-control-melanoma-in-mice/
Copy citation
Download RIS
Tags: cancer antigen targetingcell-based cancer therapychimeric antigen receptorengineered natural killer cellsGITR signalinggranzyme BHLA molecule presentationHLA-A*02:01Immunotherapyinnovative cancer immunotherapyintracellular tumor antigen recognitionMAGE-A4melanomamelanoma treatment in micemetabolic fitnessnatural killer cellsoff-tumor toxicity preventionpeptide fragment recognitionsolid tumorsolid tumor immunotherapyTCR-like CARTCR-like CAR therapytumor-specific immune responsexenograft model
